Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
Conditions
Brief summary
This phase II trial is studying how well sunitinib works in treating patients with myelodysplastic syndromes or chronic myelomonocytic leukemia. Sunitinib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth.
Detailed description
OBJECTIVES: I. Determine the overall response rate (complete response, partial response, or hematological improvement) in patients with intermediate-2 or high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia treated with sunitinib malate. II. Determine the duration of response in patients treated with this drug. III. Determine the overall survival of patients treated with this drug. IV. Determine the progression-free survival of patients treated with this drug. V. Determine the time to disease progression in patients treated with this drug. VI. Determine the toxicity of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 3-4 weeks and then monthly thereafter.
Interventions
DRUGsunitinib malate
Given orally
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* MDS syndromes meeting 1 of the following: Intermediate-2 disease, high-risk disease (IPSS score\>=1.5) * CMML: WBC\>12,000/mm\^3, Intermediate-2 disease with WBC=\<12,000/mm\^3, high-risk disease (IPSS score\>=1.5) with WBC=\<12,000/mm\^3 * Patients with insufficient/inadequate metaphases for cytogenetic analysis are eligible if bone marrow blasts are \>10% and/or 2-3 cytopenias are present * No known brain metastases * Life expectancy\>12 weeks * ECOG PS 0-2/Karnofsky PS 60-100% * Calcium=\<3.0 mmol/L * Bilirubin normal * AST and ALT=\<2.5 times upper limit of normal * Creatinine normal/creatinine clearance\>=60 mL/min
Exclusion criteria
* No history of significant ECG abnormalities including but not limited to: ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation\>=3 beats in a row); QTc prolongation (i.e.QTc interval\>=500msec) * No history of allergic reaction to compounds of similar chemical/biological composition to sunitinib malate * No NYHA class III-IV congestive heart failure * Patients with history of NYHA class II congestive heart failure who are asymptomatic on treatment are eligible * No abdominal fistula/G perforation/intraabdominal abscess within past 28 days * No serious cardiovascular disease within past 12 months including: cerebrovascular accident or transient ischemic attack, myocardial infarction, cardiac arrhythmia, stable or unstable angina, symptomatic congestive heart failure, coronary or peripheral artery bypass graft or stenting * No pulmonary embolism within past 12 months * No uncontrolled hypertension (systolic BP\>=140 mmHg/diastolic BP\>=90 mmHg) * No condition impairing ability to swallow/retain sunitinib malate tablets including: GI tract disease resulting in inability to take oral medication, requirement for IV alimentation, prior surgical procedures affecting absorption, active peptic ulcer disease * No serious/nonhealing wound, ulcer, or bone fracture * No uncontrolled pre-existing thyroid abnormality * No concurrent uncontrolled illness including ongoing/active infection * No psychiatric illness/social situation that would preclude study participation * Not pregnant/nursing * Negative pregnancy test * Fertile patients must use effective barrier contraception * 4 weeks since prior major surgery * Prior central thoracic radiotherapy that included heart in radiotherapy port allowed provided NYHA congestive heart failure=\<class II * Prior anthracycline exposure allowed provided NYHA congestive heart failure=\<class II * No other prior therapy for MDS/CMML except epoetin alfa, darbepoetin alfa, filgrastim or sargramostim * At least 2 weeks since prior epoetin alfa * At least 4 weeks since prior darbepoetin alfa * No other prior antiangiogenic agents including but not limited to: bevacizumab, sorafenib tosylate, pazopanib hydrochloride, AZD2171, vatalanib, VEGF Trap * More than 7 days since prior and no concurrent potent CYP3A4 inhibitors * More than 12 days since prior and no concurrent potent CYP3A4 inducers including: Rifampin, Rifabutin, Carbamazepine, Phenobarbital, Phenytoin, Hypericum perforatum, Efavirenz, Tipranavir * No concurrent birth control patch/oral birth control pills/depot/injectable birth control methods * No concurrent therapeutic coumarin-derivative anticoagulants * Low dose(=\<2mg) warfarin for prophylaxis of thrombosis allowed * Low molecular weight heparin allowed if INR=\<1.5 * No concurrent agents with proarrhythmic potential including: Terfenadine, Quinidine, Procainamide, Disopyramide, Sotalol, Probucol, Bepridil, Haloperidol, Risperidone, Indapamide, Flecainide acetate * No concurrent combination antiretroviral therapy for HIV-positive patients * No other concurrent investigational agents
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria | Up to 6 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number Participants With Complete, Partial or Hematologic Improvement Response | Up to 6 years | Assessed by achievement of Complete Response (CR), Partial Response (PR) or Hematologic Improvement (HI) |
| Overall Survival | At 6 months and 1 year | — |
| Progression-free Survival | At 6 months and 1 year | — |
| Time to Progression | At 6 months and 1 year | — |
| Highest Severity of Observed Adverse Events Assessed by Common Terminology Criteria or Adverse Events Version 3.0 (CTCAE v3.0) | Up to 6 years | — |
Countries
Canada, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm I Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown.
sunitinib malate: Given orally | 10 |
| Total | 10 |
Baseline characteristics
| Characteristic | Arm I |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 8 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants |
| Age, Continuous | 69 years |
| Region of Enrollment Canada | 9 participants |
| Region of Enrollment United States | 1 participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 10 / 10 |
| serious Total, serious adverse events | 4 / 10 |
Outcome results
Primary
Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria
Time frame: Up to 6 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I | Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria | 10 percentage of participants |
Secondary
Highest Severity of Observed Adverse Events Assessed by Common Terminology Criteria or Adverse Events Version 3.0 (CTCAE v3.0)
Time frame: Up to 6 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I | Highest Severity of Observed Adverse Events Assessed by Common Terminology Criteria or Adverse Events Version 3.0 (CTCAE v3.0) | 4 highest grade of adverse event reported |
Secondary
Number Participants With Complete, Partial or Hematologic Improvement Response
Assessed by achievement of Complete Response (CR), Partial Response (PR) or Hematologic Improvement (HI)
Time frame: Up to 6 years
Population: No patient achieved CR, PR or HI as response.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I | Number Participants With Complete, Partial or Hematologic Improvement Response | 0 participants |
Secondary
Overall Survival
Time frame: At 6 months and 1 year
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm I | Overall Survival | 13.9 months |
Secondary
Progression-free Survival
Time frame: At 6 months and 1 year
Population: Data were not collected
Secondary
Time to Progression
Time frame: At 6 months and 1 year
Population: Date were not collected